Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMMPOWER: AXA1665 in Liver Cirrhosis With Prior Overt Hepatic Encephalopathy
2020-005969-13Phase 2Completed
- Sponsor
- Axcella
- Start
- Jun 2021
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hepatic encephalopathy (HE) and Cirrhosis comparing AXA1665 arm with Placebo arm (2 arms). Primary endpoint: Primary: proportion of subjects with ≥ +2 change in PHES at 24 weeks. Started Jun 2021; status: completed.
02
Drugs
AXA1665
03
Conditions
hepatic encephalopathy (HE)Cirrhosis
Beyond the preview
Go deeper on 2020-005969-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005969-13.